Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

telesis bio - TBIO

TBIO

Close Chg Chg %
0.91 -0.04 -3.99%

Pre-Market

0.87

-0.04 (3.99%)

Volume: 3.23K

Last Updated:

Nov 25, 2024, 3:31 PM EDT

Trade Now

Company Overview: telesis bio - TBIO

TBIO Key Data

Open

$0.85

 Day Range

0.76 - 0.87

52 Week Range

0.76 - 15.46

 Market Cap

$1.55M

Shares Outstanding

1.78M

 Public Float

1.21M

Beta

1.86

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$28.19

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

7.77K

  

TBIO Performance

1 Week
 
 -3.99%
 
1 Month
 
 -42.52%
 
3 Months
 
 -74.45%
 
1 Year
 
 -88.01%
 
5 Years
 
 N/A
 

TBIO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About telesis bio - TBIO

Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

TBIO At a Glance

Telesis Bio, Inc.
10431 Wateridge Circle
San Diego, California 92121-2993
Phone 1-858-228-4115 Revenue 27.51M
Industry Miscellaneous Commercial Services Net Income -47,724,000.00
Sector Commercial Services 2023 Sales Growth 0.27%
Fiscal Year-end 12 / 2024 Employees 147
View SEC Filings

TBIO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.433
Price to Book Ratio 50.40
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.812
Enterprise Value to Sales 2.045
Total Debt to Enterprise Value 0.611

TBIO Efficiency

Revenue/Employee 187,136.054
Income Per Employee -324,653.061
Receivables Turnover 4.596
Total Asset Turnover 0.363

TBIO Liquidity

Current Ratio 3.709
Quick Ratio 3.217
Cash Ratio 2.362

TBIO Profitability

Gross Margin 46.705
Operating Margin -127.776
Pretax Margin -173.398
Net Margin -173.485
Return on Assets -62.889
Return on Equity -125.419
Return on Total Capital -74.664
Return on Invested Capital -73.733

TBIO Capital Structure

Total Debt to Total Equity 116.392
Total Debt to Total Capital 53.788
Total Debt to Total Assets 48.828
Long-Term Debt to Equity 13,679.832
Long-Term Debt to Total Capital 50.937
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Telesis Bio - TBIO

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
6.58M 11.04M 27.43M 27.51M
Sales Growth
+36.86% +67.93% +148.44% +0.27%
Cost of Goods Sold (COGS) incl D&A
17.17M 8.32M 14.71M 14.66M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.46M 1.57M 2.88M 4.10M
Depreciation
994.00K 1.12M 2.36M 3.59M
Amortization of Intangibles
463.00K 458.00K 515.00K 515.00K
COGS Growth
+93.21% -51.57% +76.91% -0.37%
Gross Income
(10.60M) 2.73M 12.72M 12.85M
Gross Income Growth
-159.50% +125.71% +366.79% +1.01%
Gross Profit Margin
-161.16% +24.68% +46.36% +46.70%
2020 2021 2022 2023 5-year trend
SG&A Expense
5.76M 38.10M 59.20M 48.00M
Research & Development
3.63M 14.55M 23.46M 17.50M
Other SG&A
2.14M 23.55M 35.74M 30.50M
SGA Growth
+99.27% +561.10% +55.40% -18.93%
Other Operating Expense
- - - -
-
Unusual Expense
880.00K 2.14M 719.00K 11.26M
EBIT after Unusual Expense
(17.24M) (37.51M) (47.20M) (46.41M)
Non Operating Income/Expense
(74.00K) (62.00K) (26.00K) 1.81M
Non-Operating Interest Income
- - - 1.74M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
690.00K 1.37M 1.22M 3.10M
Interest Expense Growth
-53.69% +98.41% -11.10% +155.14%
Gross Interest Expense
690.00K 1.37M 1.22M 3.10M
Interest Capitalized
- - - -
-
Pretax Income
(18.00M) (38.94M) (48.45M) (47.70M)
Pretax Income Growth
-116.88% -116.30% -24.40% +1.54%
Pretax Margin
-273.80% -352.66% -176.59% -173.40%
Income Tax
5.00K 14.00K 24.00K 24.00K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(18.01M) (38.96M) (48.47M) (47.72M)
Minority Interest Expense
- - - -
-
Net Income
(18.01M) (38.96M) (48.47M) (47.72M)
Net Income Growth
-116.94% -116.31% -24.42% +1.54%
Net Margin Growth
-273.87% -352.78% -176.68% -173.49%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(18.01M) (38.96M) (48.47M) (47.72M)
Preferred Dividends
- - - 1.30M
-
Net Income Available to Common
(18.01M) (38.96M) (48.47M) (49.02M)
EPS (Basic)
-11.0911 -23.918 -29.6123 -29.5623
EPS (Basic) Growth
-116.94% -115.65% -23.81% +0.17%
Basic Shares Outstanding
1.62M 1.63M 1.64M 1.66M
EPS (Diluted)
-11.0911 -23.918 -29.6123 -29.5623
EPS (Diluted) Growth
-116.94% -115.65% -23.81% +0.17%
Diluted Shares Outstanding
1.62M 1.63M 1.64M 1.66M
EBITDA
(14.90M) (33.80M) (43.61M) (31.05M)
EBITDA Growth
-143.57% -126.78% -29.02% +28.81%
EBITDA Margin
-226.64% -306.08% -158.96% -112.86%

Snapshot

Average Recommendation BUY Average Target Price 72.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -7.62 Median PE on CY Estimate N/A
Year Ago Earnings -29.52 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Telesis Bio - TBIO

Date Name Shares Transaction Value
May 6, 2024 Jami K. Dover Nachtsheim Director 101,679 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Annette Tumolo Director 121,363 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Annette Tumolo Director 157,769 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Annette Tumolo Director 70,129 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Franklin R. Witney Director 30,362 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Franklin R. Witney Director 70,129 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Franklin R. Witney Director 115,736 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Franklin R. Witney Director 67,382 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Annette Tumolo Director 30,362 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Gregory J. Herrema Director 30,362 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Gregory J. Herrema Director 184,677 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Christine A. Tsingos Director 30,362 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Christine A. Tsingos Director 70,129 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Christine A. Tsingos Director 104,491 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Christine A. Tsingos Director 67,382 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Jami K. Dover Nachtsheim Director 30,362 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Jami K. Dover Nachtsheim Director 70,129 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Jami K. Dover Nachtsheim Director 67,382 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Robert H. Cutler Chief Legal Officer 37,094 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Robert H. Cutler Chief Legal Officer 35,718 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.53 per share 18,930.54

Telesis Bio in the News